杜艳萍, 程群 . 骨质疏松症使用甲状旁腺激素类似物和双膦酸盐序贯治疗的机制及策略[J]. 诊断学理论与实践, 2020 , 19(03) : 219 -224 . DOI: 10.16150/j.1671-2870.2020.03.003
| [1] | 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华内分泌代谢杂志, 2017, 33(10):890-913. |
| [2] | Hanley DA, McClung MR, Davison KS, et al. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the balance of benefits and risks of long-term osteoporosis therapies[J]. Am J Med, 2017, 130(7):862,e1-e7. |
| [3] | Sims NA, Martin TJ. Coupling signals between the osteoclast and osteoblast: How are messages transmitted between these temporary visitors to the bone surface?[J]. Front Endocrinol (Lausanne), 2015, 6:41. |
| [4] | Kim BJ, Koh JM. Coupling factors involved in preserving bone balance[J]. Cell Mol Life Sci, 2019, 76(7):1243-1253. |
| [5] | Pogada P, Priemel M, Rueger JM, et al. Bone remodeling: New aspects of a key process that controls skeletal maintenance and repair[J]. Osteoporos Int, 2005, 16(Suppl 2):S18-S24. |
| [6] | Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose[J]. Toxicol Pathol, 2004, 32(4):426-438. |
| [7] | Andrews EB, Gilsenan AW, Midkiff K, et al. The US Postmarketing Surveillance Study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years[J]. J Bone Miner Res, 2012, 27(12):2429-2437. |
| [8] | Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis[J]. N Engl J Med, 2005, 353(6):555-565. |
| [9] | Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mine-ral density in postmenopausal women with osteoporosis[J]. N Engl J Med, 2001, 344(19):1434-1441. |
| [10] | Dempster DW, Lambing CL, Kostenuik PJ, et al. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: A review of preclinical and clinical data[J]. Clin Ther, 2012, 34(3):521-536. |
| [11] | Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis[J]. Arch Intern Med, 2004, 164(18):2024-2030. |
| [12] | Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis[J]. J Clin Endocrinol Metab, 2018, 103(8):2949-2957. |
| [13] | McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study[J]. J Bone Miner Res, 2018, 33(8):1397-1406. |
| [14] | Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Mana-ging osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for bone and mineral research[J]. J Bone Miner Res, 2016, 31(10):1910. |
| [15] | Khan M, Cheung AM, Khan AA. Drug-related adverse events of osteoporosis therapy[J]. Endocrinol Metab Clin North Am, 2017, 46(1):181-192. |
| [16] | Dempster DW, Zhou H, Recker RR, et al. A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ trial[J]. J Bone Miner Res, 2016, 31(7):1429-1439. |
| [17] | Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate[J]. J Clin Endocrinol Metab, 2000, 85(6):2129-2134. |
| [18] | Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)][J]. Osteoporos Int, 2004, 15(12):992-997. |
| [19] | Cosman F, Miller PD, Williams GC, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial[J]. Mayo Clin Proc, 2017, 92(2):200-210. |
| [20] | Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo(EUROFORS)[J]. J Bone Miner Res, 2009, 24(4):726-736. |
| [21] | Ebina K, Hashimoto J, Kashii M, et al. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis[J]. J Bone Miner Metab, 2017, 35(1):91-98. |
| [22] | Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the data-switch study): extension of a randomised controlled trial[J]. Lancet, 2015, 386(9999):1147-1155. |
| [23] | Bonafede MM, Shi N, Bower AG, et al. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: A US claims analysis[J]. Osteoporos Int, 2015, 26(3):1203-1212. |
| [24] | Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite[J]. Bone, 2006, 38(5):617-627. |
| [25] | Leder BZ. Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy[J]. JBMR Plus, 2018, 2(2):62-68. |
| [26] | Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxi-fene or alendronate[J]. J Bone Miner Res, 2004, 19(5):745-751. |
| [27] | Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment[J]. J Bone Miner Res, 2008, 23(10):1591-1600. |
| [28] | Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis[J]. J Clin Endocrinol Metab, 2008, 93(3):852-860. |
| [29] | Cosman F, Keaveny TM, Kopperdahl D, et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene[J]. J Bone Miner Res, 2013, 28(6):1328-1336. |
| [30] | Eiken P, Vestergaard P. Treatment of osteoporosis after alendronate or risedronate[J]. Osteoporos Int, 2016, 27(1):1-12. |
| [31] | Cosman F. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches[J]. Curr Osteoporos Rep, 2014, 12(4):385-395. |
| [32] | Miller PD, Delmtas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate[J]. J Clin Endocrinol Metab, 2008, 93(10):3785-3793. |
| [33] | Cosman F, Nieves JW, Zion M, et al. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy[J]. Osteoporos Int, 2008, 19(4):529-535. |
| [34] | Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: Differences between stopping and continuing the antiresorptive agent[J]. J Clin Endocrinol Metab, 2009, 94(10):3772-3780. |
| [35] | Geusens P, Marin F, Kendler DL, et al. Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial[J]. J Bone Miner Res, 2018, 33(5):783-794. |
| [36] | Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis[J]. N Engl J Med, 2003, 349(13):1207-1215. |
| [37] | Delmas PD, Munoz F, Black DM, et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis[J]. J Bone Miner Res, 2009, 24(9):1544-1551. |
| [38] | Guañabens N, Moro-álvarez MJ, Casado E, et al. The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment[J]. Endocrine, 2019, 64(3):441-455. |
| [39] | Cosman F. Combination therapy for osteoporosis: a reappraisal[J]. Bonekey Rep, 2014, 3:518. |
/
| 〈 |
|
〉 |
